66.61

2.87% -1.97

Pre-market: 67.49 0.88 +1.32%

Nektar Therapeutics (NKTR)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Nektar Therapeutics stock is traded at $66.61, with a volume of 533.81K. It is down -2.87% in the last 24 hours and down -28.53% over the past month. Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.

Previous Close:

$68.58

Open:

$68

24h Volume:

533.81K

Relative Volume:

0.53

Market Cap:

$2.25B

Revenue:

$55.23M

Net Income/Loss:

$-164.08M

P/E Ratio:

-9.7296

EPS:

-6.8461

Net Cash Flow:

$-208.68M

1W Performance:

-5.68%

1M Performance:

-28.53%

6M Performance:

+22.72%

1Y Performance:

+9,992%

1-Day Range:

$66.44

$69.22

1-Week Range:

$64.90

$71.00

52-Week Range:

$0.621

$109.00

Nektar Therapeutics Stock (NKTR) Company Profile

Name

Nektar Therapeutics

Sector

Healthcare (1106)

Industry

Biotechnology (618)

Phone

(415) 482-5300

Address

455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA

Employee

Twitter

@nektarnews

Next Earnings Date

2026-05-07

Latest SEC Filings

NKTR's Discussions on Twitter

Compare NKTR vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
NKTR Nektar Therapeutics	66.61	2.32B	55.23M	-164.08M	-208.68M	-6.8461
VRTX Vertex Pharmaceuticals Inc	434.52	110.03B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	638.88	67.37B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	806.46	50.76B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	297.45	40.12B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	151.56	32.68B	742.00K	-1.37B	-1.07B	-7.0731

Nektar Therapeutics Stock (NKTR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-24-26	Initiated	Wedbush	Neutral
Mar-17-26	Initiated	TD Cowen	Buy
Feb-10-26	Upgrade	William Blair	Mkt Perform → Outperform
Nov-26-25	Initiated	Citigroup	Buy
Jun-24-25	Reiterated	BTIG Research	Buy
Jun-24-25	Reiterated	H.C. Wainwright	Buy
Apr-11-25	Upgrade	Jefferies	Hold → Buy
Mar-14-25	Upgrade	Oppenheimer	Perform → Outperform
Jan-08-25	Initiated	B. Riley Securities	Buy
Dec-10-24	Initiated	H.C. Wainwright	Buy
Nov-04-24	Initiated	Piper Sandler	Overweight
Sep-30-24	Resumed	BTIG Research	Buy
Jun-28-24	Initiated	Rodman & Renshaw	Buy
Nov-20-23	Resumed	JP Morgan	Underweight
Nov-09-23	Upgrade	TD Cowen	Market Perform → Outperform
May-10-23	Upgrade	Jefferies	Underperform → Hold
Feb-24-23	Downgrade	Jefferies	Hold → Underperform
Aug-08-22	Downgrade	JP Morgan	Neutral → Underweight
May-31-22	Resumed	Jefferies	Hold
Apr-18-22	Downgrade	Goldman	Neutral → Sell
Mar-15-22	Downgrade	Cowen	Outperform → Market Perform
Mar-15-22	Downgrade	Mizuho	Buy → Neutral
Mar-14-22	Downgrade	BTIG Research	Buy → Neutral
Mar-14-22	Downgrade	BofA Securities	Neutral → Underperform
Mar-14-22	Downgrade	Stifel	Buy → Hold
Mar-14-22	Downgrade	William Blair	Outperform → Mkt Perform
Mar-09-22	Upgrade	Oppenheimer	Perform → Outperform
Nov-08-21	Upgrade	The Benchmark Company	Hold → Buy
Sep-10-21	Initiated	BofA Securities	Neutral
Jun-28-21	Upgrade	Stifel	Hold → Buy
May-18-21	Resumed	Goldman	Neutral
Feb-22-21	Downgrade	The Benchmark Company	Buy → Hold
Jan-06-21	Initiated	Stifel	Hold
Sep-14-20	Initiated	JP Morgan	Neutral
Jun-10-20	Downgrade	CFRA	Hold → Sell
May-12-20	Reiterated	H.C. Wainwright	Neutral
Apr-22-20	Initiated	The Benchmark Company	Buy
Mar-30-20	Upgrade	Goldman	Sell → Neutral
Mar-04-20	Initiated	Barclays	Overweight
Feb-03-20	Upgrade	Mizuho	Neutral → Buy
Oct-24-19	Initiated	Oppenheimer	Perform
Oct-08-19	Downgrade	Goldman	Buy → Sell
Aug-09-19	Downgrade	JP Morgan	Overweight → Neutral
Aug-09-19	Downgrade	Jefferies	Buy → Hold
Aug-09-19	Downgrade	Mizuho	Buy → Neutral
Mar-15-19	Initiated	SVB Leerink	Mkt Perform
Dec-13-18	Initiated	Goldman	Buy
Jun-11-18	Downgrade	H.C. Wainwright	Buy → Neutral
Jun-04-18	Reiterated	H.C. Wainwright	Buy
Apr-20-18	Initiated	Seaport Global Securities	Buy
Apr-13-18	Resumed	Piper Jaffray	Overweight
Apr-06-18	Reiterated	Mizuho	Buy
Apr-02-18	Resumed	H.C. Wainwright	Buy

View All

Nektar Therapeutics Stock (NKTR) Latest News

May 25, 2026

Bronstein, Gewirtz & Grossman, LLC Is Investigating Nektar Therapeutics (NKTR) And Encourages Stockholders to Connect - ACCESS Newswire

May 25, 2026

May 24, 2026

What to Know About This Fund's $10 Million Nektar Bet Ahead of a Key Phase 3 Launch - AOL.com

May 24, 2026

A Look At Nektar Therapeutics (NKTR) Valuation After Prosight’s US$10 Million Purchase Ahead Of Phase 3 Trial - simplywall.st

May 24, 2026

May 23, 2026

What to Know About This Fund's $10 Million Nektar Bet Ahead of a Key Phase 3 Launch - The Motley Fool

May 23, 2026

May 22, 2026

Nektar TherapeuticsCommon Stock (NQ: NKTR - The Chronicle-Journal

May 22, 2026

May 21, 2026

Nektar Therapeutics R&D chief sells $13,036 in shares - Investing.com UK

May 21, 2026

Nektar Therapeutics CEO Robin Howard W sells $29,086 in shares By Investing.com - Investing.com South Africa

May 21, 2026

Nektar Therapeutics R&D chief sells $13,036 in shares By Investing.com - Investing.com Canada

May 21, 2026

Nektar Therapeutics CEO Robin Howard W sells $29,086 in shares - Investing.com

May 21, 2026